<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Radical prostatectomy for localized prostate cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Radical prostatectomy for localized prostate cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Radical prostatectomy for localized prostate cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">W Robert Lee, MD, MS, MEd</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H24077712"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Standard management options for men with clinically localized prostate cancer include radical prostatectomy; radiation therapy (RT), including external beam RT and/or brachytherapy; and, for appropriately selected patients, active surveillance. Patients treated with RT who were classified as high risk based upon pretreatment assessment and those managed with radical prostatectomy who have significant adverse pathologic findings (positive margins, seminal vesicle invasion, persistent elevation of serum prostate specific antigen [PSA]) may require a combined modality approach. </p><p>The role of radical prostatectomy in the treatment of clinically localized prostate cancer will be reviewed here. Overall treatment options for men with newly diagnosed prostate cancer and the factors influencing the choice of therapy are discussed separately based upon the risk of recurrence and the extent of disease:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">"Localized prostate cancer: Risk stratification and choice of initial treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6940.html" rel="external">"Initial approach to low- and very low-risk clinically localized prostate cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6947.html" rel="external">"Initial management of regionally localized intermediate-, high-, and very high-risk prostate cancer and those with clinical lymph node involvement"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">"Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer"</a>.)</p><p></p><p class="headingAnchor" id="H167060109"><span class="h1">SURVIVAL IMPACT OF RADICAL PROSTATECTOMY</span><span class="headingEndMark"> — </span>Randomized clinical trials provide evidence that radical prostatectomy improves overall survival or delays the development of metastatic disease compared with observation (watchful waiting) [<a href="#rid1">1-5</a>]. The trials did not include definitive therapy at the first evidence of disease progression, do not compare the impact of radical prostatectomy with other active treatment approaches, and need to be distinguished from active surveillance, where definitive therapy is delayed and instituted only when evidence of progression is present.</p><p class="bulletIndent1"><span class="glyph">●</span>In the Scandinavian Prostate Cancer Group 4 trial, 695 men with clinical stage T1 or T2 prostate cancer were randomly assigned to radical prostatectomy or watchful waiting, with active therapy deferred until advanced disease was present [<a href="#rid3">3</a>]. With a maximum follow-up of 23 years (median 13 years), men randomized to radical prostatectomy had a significantly lower incidence of death from all causes (56 versus 69 percent), death from prostate cancer (18 versus 29 percent), distant metastases (26 versus 38 percent), and use of androgen deprivation therapy (43 versus 67 percent) compared with those assigned to watchful waiting. The benefits were most pronounced in those less than 65 years of age at diagnosis and in those with intermediate-risk disease. In a later analysis with a maximum 29 year follow-up (median 23.6 years), the cumulative incidence of death from prostate cancer was 19.6 percent in the prostatectomy group and 31.3 percent with watchful waiting [<a href="#rid6">6</a>]. A mean of 2.9 extra years of life were gained with radical prostatectomy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the PIVOT trial, 731 men with T1-T2NxM0 prostate cancer were randomly assigned to radical prostatectomy or observation [<a href="#rid2">2,4,7</a>]. Men assigned to observation were offered palliative therapy for symptomatic or metastatic progression. Although the difference in overall survival and prostate cancer mortality did not reach statistical significance, the trial did not complete its planned accrual and was underpowered; it also included predominantly older men with substantial comorbidities. In the latest analysis with a minimum follow-up of death or 15 years and a maximum follow-up of 22 years, 246 of 364 patients assigned to surgery had died, and 269 of 367 assigned to observation had died (hazard ratio [HR] for death 0.84, 95% CI 0.70-1.00) [<a href="#rid7">7</a>]. The restricted mean survival in the surgical group was 13.6 years, compared with 12.6 years with observation, with a mean of one year gained with surgery at a median 22 years of follow-up. </p><p></p><p class="bulletIndent1">Disease progression (local, regional, or systemic) was significantly less frequent in those managed with radical prostatectomy (41 versus 68 percent, HR 0.39, 95% CI 0.32-0.48) [<a href="#rid4">4</a>]. Additional treatment for prostate cancer was eventually required in 33.5 percent of those managed with radical prostatectomy and 59.7 percent of those managed with observation. Erectile dysfunction and urinary incontinence were more frequent with surgery compared with observation (14.6 versus 5.4 and 17.3 versus 4.4 percent, respectively).</p><p></p><p>The outcomes following radical prostatectomy compared with other treatment approaches are based upon risk stratification. The only large-scale data came from the Prostate Testing for Cancer and Treatment (ProtecT) trial that is being conducted in the United Kingdom. Patients with prostate cancer detected at prostate-specific antigen (PSA) screening were randomly assigned to active surveillance, radical prostatectomy, or definitive radiation therapy [<a href="#rid8">8,9</a>]. In the initial report of this trial, there was no significant difference in the 10 year cancer-specific survival or overall survival rates between the different treatment modalities. However, there was an increased frequency of metastatic disease and clinical progression with active surveillance, and there were only a very limited number of deaths related to prostate cancer. Detailed results and limitations of the ProtecT trial are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6940.html" rel="external">"Initial approach to low- and very low-risk clinically localized prostate cancer", section on 'ProtecT trial'</a>.)</p><p>Radical prostatectomy also has a role in patients with more extensive local disease and may be associated with a survival advantage. (See  <a class="medical medical_review" href="/z/d/html/6947.html" rel="external">"Initial management of regionally localized intermediate-, high-, and very high-risk prostate cancer and those with clinical lymph node involvement", section on 'Radical prostatectomy'</a>.)</p><p class="headingAnchor" id="H1302078"><span class="h1">PATIENT SELECTION</span><span class="headingEndMark"> — </span>Radical prostatectomy is a treatment option for patients with localized prostate cancer, along with external beam radiation therapy, brachytherapy, and, in some cases, active surveillance. </p><p>The choice of therapy depends upon an informed patient decision incorporating knowledge about the potential advantages and disadvantages associated with different treatment approaches. </p><p>Radical prostatectomy is generally not indicated for patients with distant metastases, although new clinical trials are evaluating its role as a part of a multimodal approach in men who present with oligometastatic disease [<a href="#rid10">10</a>]. Neither is prostatectomy indicated when there is tumor fixation to adjacent structures.</p><p>The factors influencing the choice of prostatectomy rather than external beam radiation therapy, brachytherapy, or active surveillance are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6940.html" rel="external">"Initial approach to low- and very low-risk clinically localized prostate cancer"</a>.)</p><p class="headingAnchor" id="H3106758680"><span class="h2">Preoperative preparation</span><span class="headingEndMark"> — </span>Preoperative counseling that includes the spouse or partner is essential to address the practical and emotional issues surrounding radical prostatectomy. Presurgical psychosocial interventions including a focus on stress management may be useful in improving quality of life following surgery [<a href="#rid11">11</a>]. In addition, patients should be counseled regarding the importance of modifying health-related behaviors or risk factors, such as smoking and obesity [<a href="#rid12">12</a>]. </p><p>One of the most important goals prior to treatment is to set reasonable expectations for the short-term and long-term effects of surgery on activity level, continence, and potency. Emphasis is placed on the type of anesthesia to be used, whether lymphadenectomy will be performed, and whether a nerve-sparing procedure is contemplated, as well as the anticipated length of hospital stay.</p><p class="headingAnchor" id="H24077719"><span class="h1">SURGICAL TREATMENT</span><span class="headingEndMark"> — </span>Radical prostatectomy, which implies total removal of the prostate and the seminal vesicles, can be safely performed via a variety of approaches (open retropubic or perineal; laparoscopic transperitoneal or extraperitoneal; robotic transperitoneal, extraperitoneal, transvesical [through the bladder], or transperineal). The approach is mostly determined by the skill and experience of the surgeon, though disease extent is also important. </p><p class="headingAnchor" id="H1413045884"><span class="h2">Radical prostatectomy</span><span class="headingEndMark"> — </span>In resource-rich countries, such as the United States, radical prostatectomy is most commonly performed robotically [<a href="#rid13">13-15</a>]. When performed by experienced surgeons, robotic-assisted radical prostatectomy (RARP) has similar oncologic and functional results, but shorter hospital stay, shortened catheter times, and fewer major complications, compared with open radical prostatectomy [<a href="#rid16">16,17</a>]. </p><p>A 2017 practice guideline jointly sponsored by the American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO), and later endorsed by the American Society of Clinical Oncology (ASCO) in 2018, considers open and RARP to be similar in cancer control, continence recovery, and sexual recovery [<a href="#rid12">12</a>]. The advantages of minimally invasive techniques, aside from a smaller incision, mainly lie in perioperative outcomes such as reduced blood loss and fewer postoperative complications [<a href="#rid18">18</a>]. </p><p>A 2017 Cochrane review of two randomized trials showed that minimally invasive and open prostatectomy resulted in similar urinary and sexual quality-of-life outcomes. Overall and serious complication rates were also comparable, while patients had shorter hospital stay and fewer blood transfusions after minimally invasive prostatectomy. However, oncologic outcomes were not addressed with high-quality data [<a href="#rid19">19</a>]. </p><p>One of the trials included in the Cochrane review cited above was updated in 2018 [<a href="#rid20">20,21</a>]. In a report of early outcomes, there was no significant difference in urinary or sexual function scores through 12 weeks, nor was there a significant difference in the incidence of positive surgical margins [<a href="#rid20">20</a>]. At 24 months after surgery, there was also no difference in urinary function scores or sexual function scores between the two groups. And although there was a higher rate of biochemical recurrence after open surgery (9 versus 3 percent), the discrepancy may be due to different postoperative management and use of additional cancer treatment [<a href="#rid21">21</a>]. </p><p>A 2015 Swedish prospective, controlled, nonrandomized trial (LAPPRO) reported that, at eight years after surgery, urinary incontinence was not significantly different between RARP and open prostatectomy (27 versus 29 percent). Erectile dysfunction was significantly lower in the RARP group (66 versus 70 percent). Prostate cancer-specific mortality was significantly lower in the RARP group (40/2699 versus 25/885; adjusted risk ratio 0.56, 95% CI 0.34-0.93). However, a causal relationship could not be inferred, due to the nonrandomized study design [<a href="#rid17">17</a>].</p><p>Although laparoscopic radical prostatectomy offers the benefits of minimally invasive surgery without the need for specialized equipment and high costs associated with the surgical robot, it is considered by many to be a difficult technique with a steep learning curve and therefore is not often adopted in North America. In a randomized, patient-blinded trial (LAP-01), RARP resulted in significantly better continence recovery than laparoscopic prostatectomy at three months (continence rate 54 versus 46 percent) [<a href="#rid22">22</a>].</p><p>The experience of the surgeon is a critical factor associated with a successful outcome following radical prostatectomy regardless of technique since the results with all surgical approaches are associated with a significant learning curve [<a href="#rid23">23-28</a>]. Conversely, large retrospective series comparing open, laparoscopic, and RARP performed by expert surgeons at high-volume centers showed no difference in functional outcomes [<a href="#rid29">29</a>].</p><p>In several reports, extraperitoneal single-port robotic radical prostatectomy has been performed as outpatient surgery or only required overnight observation [<a href="#rid30">30-32</a>]. </p><p class="headingAnchor" id="H683372924"><span class="h2">Nerve-sparing approach</span><span class="headingEndMark"> — </span>Erectile function following radical prostatectomy depends upon preservation of the autonomic cavernous nerves, located within the neurovascular bundles. Because a nerve-sparing approach is associated with better erectile function recovery than non-nerve-sparing approaches [<a href="#rid12">12</a>], every effort should be made to preserve the bilateral neurovascular bundles during proctectomy as long as cancer control is not compromised. (See <a class="local">'Erectile dysfunction'</a> below.)</p><p>For patients with no evidence of tumor involving the neurovascular bundle, we recommend that a nerve-sparing approach be incorporated into the radical prostatectomy. This approach is associated with faster return of urinary continence and a lower frequency of erectile dysfunction in men who were potent prior to surgery. </p><p>In a 2017 systematic review and meta-analysis of 124 mostly observational studies, the risk of incontinence was lower in nerve-sparing cases (relative risk [RR] 0.75, 95% CI 0.65-0.85 and RR 0.61, 95% CI 0.44-0.84) at 3 and 12 months, respectively. The relative risk of erectile dysfunction with nerve sparing was 0.77 (95% CI 0.70-0.85) at 3 months and 0.53 (95% CI 0.39-0.71) at 12 months [<a href="#rid33">33</a>]. Nerve sparing did not increase the risk of positive surgical margins in patients with pT2 or pT3 disease, due to appropriate patient selection.</p><p>Nerve-sparing radical prostatectomy can be performed safely in men with pathologic extraprostatic extension as long as the neurovascular bundles are not involved. The decision to perform a nerve-sparing approach is influenced by the size and location of the tumor based on preoperative magnetic resonance imaging (MRI) but ultimately made during surgery based upon visual inspection of the gland and its relationship to the nerve bundle. If there is a clinical suspicion of extraprostatic extension involving the neurovascular bundles, intraoperative frozen section analysis to ensure complete tumor excision may be useful. </p><p>Multiparametric MRI (mpMRI) of the prostate may also be useful in guiding the surgical approach. (See  <a class="medical medical_review" href="/z/d/html/97482.html" rel="external">"The role of magnetic resonance imaging in prostate cancer"</a>.)</p><p class="headingAnchor" id="H2577070854"><span class="h2">Retzius-sparing approach</span><span class="headingEndMark"> — </span>Retzius-sparing robotic-assisted radical prostatectomy (RS-RARP) avoids dissection of the retropubic space of Retzius and instead dissects the posterior space of Douglas (rectovesical pouch) [<a href="#rid34">34</a>]. At least in theory, RS-RARP can improve postoperative urinary continence by preserving the bladder neck and urethral anatomy through a posterior plane of dissection [<a href="#rid35">35</a>]. However, RS-RARP has a more limited working space compared with standard RARP.</p><p>A 2020 Cochrane meta-analysis of five trials concluded that the Retzius-sparing approach resulted in a lower urinary incontinence rate at up to six months but a higher positive margin rate [<a href="#rid36">36</a>]. Longer-term oncologic and functional outcomes are required before Retzius-sparing radical prostatectomy can be recommended for wide-spread use. </p><p class="headingAnchor" id="H3342647306"><span class="h2">Perineal radical prostatectomy</span><span class="headingEndMark"> — </span>Perineal radical prostatectomy recapitulates the retropubic approach via a perineal, rather than abdominal, incision. It was the favored radical prostatectomy approach for many years until the description of the retropubic radical prostatectomy, whose advantages included a large working space and more familiar anatomy. The adoption and rapid diffusion of robotic technology brought a new interest in the perineal approach. Although originally an open procedure [<a href="#rid37">37</a>], perineal radical prostatectomy is being performed robotically using a single-port platform at specialized centers [<a href="#rid38">38-42</a>].</p><p>Perineal radical prostatectomy is a reasonable option for men with low-risk primary tumors and relatively small prostates (eg, Gleason score &lt;6, serum prostate-specific antigen [PSA] &lt;10 ng/mL, and a prostate gland &lt;80 g) and in whom a pelvic lymph node dissection is not indicated. Perineal radical prostatectomy, open or robotic, may be advantageous in patients with prior abdominal surgery, though the robotic transvesical approach similarly avoids the abdomen and allows for more working room than the perineal approach. Perineal approaches are associated with longer times to recovery of erections [<a href="#rid43">43,44</a>].</p><p class="headingAnchor" id="H24077780"><span class="h2">Pelvic lymph node dissection</span><span class="headingEndMark"> — </span>Prostatectomy may be combined with a pelvic lymph node dissection if there is significant risk of lymph node involvement.</p><p class="headingAnchor" id="H1302101"><span class="h3">Indications for lymph node dissection</span><span class="headingEndMark"> — </span>Since the widespread introduction of PSA testing, most patients are diagnosed with localized disease, and there has been a concomitant decrease in the percentage of patients with regional lymph node involvement at diagnosis [<a href="#rid45">45-47</a>]. However, the decreased utilization of PSA screening due to changes in screening guidelines may be contributing to an increased incidence of men with metastatic disease (from 2010 to 2014) and a decreased incidence of men with low-risk prostate cancer [<a href="#rid48">48-51</a>]. (See  <a class="medical medical_review" href="/z/d/html/7567.html" rel="external">"Screening for prostate cancer", section on 'PSA testing'</a>.)</p><p>Key factors that are associated with an increased risk of occult lymph node metastases include a higher clinical tumor stage, percentage of Gleason pattern 4 tumor, presence of cribriform and/or intraductal morphology [<a href="#rid52">52,53</a>], and higher serum PSA. The need for pelvic lymph node dissection in conjunction with radical prostatectomy is determined by the risk of regional lymph node involvement, which is based upon the extent of the local tumor (T stage), serum PSA, and Gleason score. (See  <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">"Localized prostate cancer: Risk stratification and choice of initial treatment", section on 'Risk-stratified approach to treatment of adenocarcinomas'</a>.)</p><p>In their 2022 guidelines, the American Urological Association (AUA) recognizes that pelvic lymphadenectomy provides staging information, which may guide future management, but does not have consistently documented improvement in metastasis-free, cancer-specific, or overall survival [<a href="#rid54">54</a>]. This is based on a 2017 systematic review and meta-analysis of 44 studies showing conflicting results on biochemical and clinical recurrence, no significant differences for survival, but greater adverse outcomes in terms of operating time, blood loss, length of stay, and postoperative complications with more extensive pelvic lymph node dissection (PLND) [<a href="#rid55">55</a>]. </p><p>The AUA suggests that clinicians use nomograms to select patients for lymphadenectomy. Several such nomograms exist to facilitate selection of patients for PLND [<a href="#rid56">56-59</a>]. The National Comprehensive Cancer Network (NCCN) recommends performing PLND when the risk of lymph node metastasis is greater than 2 percent based on a nomogram [<a href="#rid60">60</a>]. The European Association of Urology (EAU) guidelines recommend PLND for men with high-risk and intermediate-risk disease having at least a 5 percent probability of nodal metastases [<a href="#rid61">61</a>].</p><p>The oncologic benefit of PLND for prostate cancer remains controversial. An improvement in survival from a PLND has not been demonstrated in randomized trials [<a href="#rid62">62,63</a>]. Although lymph node dissection provides important staging and prognostic information, it is unlikely to have major therapeutic benefit. (See <a class="local">'Oncologic outcomes'</a> below.)</p><p>Furthermore, newer imaging agents such as prostate-specific membrane antigen (PSMA) are refining risk assessment and may soon rewrite the indications for PLND [<a href="#rid64">64,65</a>]. There are also studies underway using intraoperative imaging to help tailor the extent of the PLND.</p><p class="headingAnchor" id="H2323997484"><span class="h3">Extent of lymph node dissection</span><span class="headingEndMark"> — </span>The extent of a PLND has a major impact on the frequency with which positive lymph nodes are detected as well as on the incidence of complications. The optimal extent of PLND is uncertain, but the available evidence suggests that an extended dissection is preferable, especially in patients with very-high-risk disease [<a href="#rid47">47,66</a>]. </p><p>Historically, PLND was limited to the obturator fossa (limited) or associated with the external iliac vein (standard). However, the primary lymphatic drainage of the prostate often bypasses these nodes and goes directly to the common iliac, hypogastric, paraaortic, presacral, or perirectal lymph nodes. A more extensive dissection (extended) including internal iliac nodes not only yields greater numbers of positive nodes but also can identify lymph node involvement when the nodes within a more limited template are negative [<a href="#rid47">47,67-69</a>].</p><p>In a trial of 300 patients with intermediate or high-risk prostate cancer, extended PLND provided better pathological staging, but differences in early oncologic outcomes were not demonstrated. One subgroup analysis suggested a potential biochemical recurrence-free survival benefit in patients with higher-grade cancers [<a href="#rid62">62</a>] However, these findings should be considered hypothesis generating, and further randomized controlled trials with larger cohorts and longer follow-up are necessary to better define the role of extended PLND during radical prostatectomy.</p><p>In another trial of 1440 patients, extended PLND did not improve biochemical recurrence-free survival over limited PLND for men with clinically localized prostate cancer. However, there were smaller-than-expected differences in nodal count (12 versus 14 nodes) and the rate of positive nodes between the two templates (12 versus 14 percent) [<a href="#rid63">63</a>]. </p><p>Patients should be counseled regarding the potential complications associated with PLND, such as lymphocele formation, and their treatment [<a href="#rid12">12</a>]. (See <a class="local">'Surgical outcomes'</a> below.)</p><p class="headingAnchor" id="H3857826179"><span class="h2">Follow-up after surgery</span><span class="headingEndMark"> — </span>Patients with adverse laboratory or pathology features following prostatectomy (ie, positive margins, seminal vesicle invasion, extracapsular extension, or detectable PSA) should consider postoperative adjuvant or early salvage radiation therapy. In contemporary practice, adjuvant therapy is mainly indicated for those with persistently detectable PSA.</p><p class="headingAnchor" id="H1302131"><span class="h3">Pathologic staging</span><span class="headingEndMark"> — </span>Patients who are managed with radical prostatectomy are restaged after surgery based upon the extent of disease in the surgical resection specimen. Such patients may be reclassified, based upon the extent of the primary tumor and/or the presence of microscopic involvement of regional lymph nodes. The information from pathologic staging can provide important information regarding prognosis and help guide future therapy.</p><p>The management of patients with pathologic T3 disease, margin-positive prostate cancer, or microscopic lymph node involvement is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6934.html" rel="external">"Prostate cancer: Postoperative management of pathologic stage T3 disease, positive surgical margins, and lymph node involvement following radical prostatectomy", section on 'Pathologic versus clinical staging'</a>.) </p><p class="headingAnchor" id="H781215816"><span class="h3">Assessment of treatment efficacy</span><span class="headingEndMark"> — </span>Following radical prostatectomy, the serum level of PSA should become undetectable since all normal prostate tissue as well as the tumor is removed. Although in principle this is a straightforward, definitive endpoint, in fact there is no consensus as to what constitutes a failure after surgery. Most series use a PSA &gt;0.2 ng/mL, but ultrasensitive assays can reliably detect recurrences years earlier. Newer genomic classifiers can assess the risk of developing metastatic disease at the time of biochemical recurrence [<a href="#rid70">70,71</a>]. (See  <a class="medical medical_review" href="/z/d/html/6950.html" rel="external">"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification", section on 'After radical prostatectomy'</a>.)</p><p>Surveillance strategies after treatment for localized prostate cancer are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6928.html" rel="external">"Follow-up surveillance after definitive local treatment for prostate cancer"</a>.)</p><p class="headingAnchor" id="H1319776432"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H24077788"><span class="h2">Functional outcomes</span></p><p class="headingAnchor" id="H24077796"><span class="h3">Erectile dysfunction</span><span class="headingEndMark"> — </span>Most men experience at least temporary erectile dysfunction even after nerve-sparing procedures. Recovery of erectile function is influenced by multiple factors, including age, pretreatment sexual functioning, and type of surgery (nerve-sparing versus non-nerve-sparing). A validated model that may be useful in counseling patients has been developed to predict sexual function recovery at 12 and 24 months after radical prostatectomy [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H24077818"><span class="h4">Incidence and time course</span><span class="headingEndMark"> — </span>The frequency of erectile dysfunction depends upon the definition of erectile dysfunction and source of information. Potency rates as high as 76 to 86 percent have been reported by individual surgeons and centers performing nerve-sparing surgery on carefully selected men who then use phosphodiesterase inhibitors such as <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> [<a href="#rid73">73,74</a>]. In contrast, sexuality problems (eg, poor erections, difficulty with orgasm) were a moderate or serious problem in 59 percent of men two months after in a series of 603 patients who had undergone radical prostatectomy [<a href="#rid75">75</a>]. Although there was some gradual improvement with time, 43 percent still reported such problems two years after prostatectomy.</p><p>The recovery of erectile function can be delayed and can continue even beyond two years [<a href="#rid76">76,77</a>]. For those men who recover function, the available evidence indicates that such benefit can be maintained for at least 10 years.</p><p>The likelihood of regaining potency following radical prostatectomy decreases with increasing age. In one series, the potency rate after surgery was 86 percent in men in their 40s and 80, 60, and 42 percent for men in their 50s, 60s, and 70s, respectively [<a href="#rid73">73</a>]. Older men experience higher rates of permanent erectile dysfunction after prostatectomy compared with younger men [<a href="#rid12">12</a>]. </p><p class="headingAnchor" id="H24077825"><span class="h4">Management</span><span class="headingEndMark"> — </span>Penile sensation and the ability to have an orgasm are preserved even if the erectile nerves are removed during radical prostatectomy, leaving several options for treatment of erectile dysfunction [<a href="#rid78">78</a>]. These include the use of oral phosphodiesterase 5 (PDE5) inhibitors, vacuum-assisted erection devices, penile self-injection (prostaglandin E1, <a class="drug drug_general" data-topicid="9739" href="/z/d/drug information/9739.html" rel="external">papaverine</a>, <a class="drug drug_general" data-topicid="9767" href="/z/d/drug information/9767.html" rel="external">phentolamine</a>), and intraurethral <a class="drug drug_general" data-topicid="8459" href="/z/d/drug information/8459.html" rel="external">alprostadil</a>. Sexual counseling should be recommended for men and their partners as it may increase the use of and satisfaction with medical therapies. (See  <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">"Treatment of male sexual dysfunction"</a> and  <a class="medical medical_review" href="/z/d/html/8092.html" rel="external">"Surgical treatment of erectile dysfunction"</a>.)</p><p>PDE5 inhibitors are most helpful in men who have undergone a nerve-sparing procedure. As an example, in one study of 91 men presenting with erectile dysfunction following radical prostatectomy, the response rates to <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> in men who had undergone bilateral nerve-sparing, unilateral nerve-sparing, and a non-nerve-sparing approach were 72, 50, and 15 percent, respectively [<a href="#rid79">79</a>].</p><p>The response to <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> increases with time following radical prostatectomy [<a href="#rid80">80</a>]. In a study in which 95 percent of men had undergone nerve-sparing procedures, 60 percent reported benefit from sildenafil at 18 to 24 months after surgery, significantly higher than the 29 percent who reported benefit in the first six months after surgery [<a href="#rid81">81</a>].</p><p>Emerging treatment for erectile dysfunction after radical prostatectomy includes injection of stem cells into the corpus cavernosum [<a href="#rid82">82</a>] and low-intensity extracorporeal shock wave treatment (LI-ESWT) to induce neovascularization [<a href="#rid83">83</a>]. </p><p class="headingAnchor" id="H705967483"><span class="h4">Penile rehabilitation</span><span class="headingEndMark"> — </span>Penile rehabilitation beginning shortly after surgery with oral phosphodiesterase inhibitors, vacuum-assisted devices, or prostaglandin E1 injections has been advocated to minimize the long-term incidence of erectile dysfunction, although the effectiveness of this approach is uncertain [<a href="#rid84">84-88</a>].</p><p>Early penile rehabilitation with oral agents remains controversial. On-demand treatment with a PDE5 inhibitor appears to be as effective as penile rehabilitation following bilateral nerve-sparing radical prostatectomy.</p><p>Two large double-blind randomized trials have been conducted, one with <a class="drug drug_general" data-topicid="10172" href="/z/d/drug information/10172.html" rel="external">vardenafil</a> [<a href="#rid89">89</a>] and the other with <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> [<a href="#rid90">90</a>]. In both trials, patients were randomly assigned to a daily PDE5 inhibitor, on-demand PDE5 inhibitor, or placebo for nine months, followed by a two-month washout period. In both trials, there were no statistically significant differences between the two PDE5 inhibitor regimens, and both were superior to placebo. Furthermore, after the two-month washout period, there were no statistically significant differences between treatment groups in response to PDE5 inhibition.</p><p>Animal model data suggest that perioperative use of oral phosphodiesterase inhibitors helps recovery. In a pilot human trial, <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> started before nerve-sparing RARP has been found to lead to better recovery of erectile dysfunction than does postoperative penile rehabilitation [<a href="#rid91">91</a>]. The author's routine is to use tadalafil (2.5 mg for three days preoperatively and 30 days postoperatively), followed by <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> 100 mg two to three times per week along with sexual stimulation to orgasm as soon as the patient recovers continence. Injection treatment is added at eight weeks if desired by patients whose erections have not returned.</p><p>LI-ESWT, which can cause a biological change that induces neovascularization, has also been used as a treatment for erectile dysfunction after radical prostatectomy [<a href="#rid83">83</a>]. In a nonrandomized comparative study comparing early LI-ESWT plus daily <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> therapy with tadalafil only, the proportion of patients with erection hardness scores (EHS) ≥3 (4/39 versus 12/41) was significantly higher in the LI-ESWT plus tadalafil group [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H24077840"><span class="h3">Urinary incontinence</span><span class="headingEndMark"> — </span>Damage to the urinary sphincter can lead to urinary incontinence following radical prostatectomy. Although complete urinary incontinence is uncommon following radical prostatectomy, most men do experience some degree of urinary incontinence after radical prostatectomy, particularly stress incontinence. Older men experience higher rates of permanent urinary incontinence after prostatectomy compared with younger men [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/15176.html" rel="external">"Urinary incontinence after prostate treatment", section on 'Pathophysiology'</a>.)</p><p>The incidence of incontinence depends upon its definition, the time elapsed since surgery, and the surgical approaches and techniques used. In a study that compared four different techniques of RARP, the 0 pad continence rates of anterior, posterior, hybrid posterior-anterior, and transvesical approaches were 15, 42, 45, and 8 percent at one week and 35, 66, 64, and 25 percent at one month [<a href="#rid93">93</a>]. Bladder neck preservation was the only significant predictor of total continence recovery in adjusted analysis. Another study reported that routine implementation of standard full functional-length urethral sphincter and neurovascular bundle preservation with intraoperative frozen section technique resulted in a long-term continence rate of 91 percent, compared with 63 percent in standard RARP [<a href="#rid94">94</a>].</p><p>Urinary incontinence typically improves with time following retropubic radical prostatectomy. In a multi-institution analysis that included 603 patients who had undergone radical prostatectomy, 52 percent of patients reported some urine leakage more than once a day two months after surgery [<a href="#rid75">75</a>]. By 12 and 24 months, this had decreased to approximately 15 percent. Approximately 7 percent continued to consider urinary symptoms to be a moderate or large problem at two years. A validated model that may be useful in counseling patients has been developed to predict continence recovery at 24 months after radical prostatectomy [<a href="#rid95">95</a>]. </p><p>How long additional improvement in urinary function can be observed is uncertain. One longitudinal study of urinary continence in 1788 men suggested that there was no further improvement in the continence rate and that between 2 and 10 years there was a slight decrease in urinary continence [<a href="#rid96">96</a>]. By contrast, a second study of 1003 men with impaired urinary function at 12 months found that there was continued improvement at least through four years [<a href="#rid77">77</a>].</p><p>Pelvic floor muscle exercises can accelerate the recovery of urinary continence [<a href="#rid97">97</a>]. However, the use of such exercises prior to surgery does not appear to provide additional benefit [<a href="#rid98">98</a>]. Fewer than 1 percent of patients ultimately require surgical placement of a sling or an artificial sphincter. (See  <a class="medical medical_review" href="/z/d/html/15176.html" rel="external">"Urinary incontinence after prostate treatment", section on 'Management of incontinence'</a>.)</p><p class="headingAnchor" id="H24079816"><span class="h3">Urethral strictures</span><span class="headingEndMark"> — </span>Urethral strictures following radical prostatectomy may be due to bladder neck contracture or narrowing of the urethra at more distal sites. Urethral stricture may be manifested by symptoms of decreased urinary stream, urinary retention, or overflow incontinence.</p><p>The incidence of urethral stricture or bladder neck contracture was between 8 and 11 percent in the era of open radical prostatectomy [<a href="#rid99">99,100</a>]. That rate is significantly lower after RARP than open radical prostatectomy (1.6 versus 8.3 percent) in contemporary series [<a href="#rid16">16</a>]. </p><p>Most contractures can be easily managed with simple dilation. Dense strictures may require endoscopic incision [<a href="#rid101">101</a>] and rarely require open surgical repair. (See  <a class="medical medical_review" href="/z/d/html/15175.html" rel="external">"Strictures of the adult male urethra"</a>.)</p><p class="headingAnchor" id="H362249447"><span class="h3">Lower urinary tract symptoms</span><span class="headingEndMark"> — </span>Men who undergo radical prostatectomy for localized prostate cancer frequently have pretreatment lower urinary tract symptoms (LUTS) that are due to benign prostatic hyperplasia (BPH) rather than tumor. Radical prostatectomy may partially reverse or prevent the progression of such symptoms [<a href="#rid102">102</a>]. </p><p>Although the natural history of BPH can be variable, the symptoms of BPH in some men appear to improve following surgery. In a prospective 15 year longitudinal study, the proportions of men with clinically significant LUTS were smaller at all time points after retropubic prostatectomy, except 3 months and 15 years, than at baseline [<a href="#rid103">103</a>]. Another prospective study found that the benefit of radical prostatectomy in men with obstructive or irritative urinary symptoms was greatest in those with large prostate size [<a href="#rid75">75</a>]. The potential impact of radical prostatectomy on such symptoms may be a factor when choosing the definitive treatment of localized prostate cancer [<a href="#rid102">102</a>], and for that reason radical prostatectomy may be favored over external radiation or brachytherapy in men with significant LUTS. </p><p class="headingAnchor" id="H24077868"><span class="h2">Surgical outcomes</span><span class="headingEndMark"> — </span>Perioperative morbidity rates of radical prostatectomy are generally under 10 percent. Serious complications include myocardial infarction and thromboembolic, infectious, and neurologic events, but most complications are minor and resolve without sequelae. Operative mortality rates in most series are less than 1 percent, even in older men [<a href="#rid16">16,104,105</a>]. </p><p>A 2017 systematic review of 50 studies reported the following perioperative complications (with incidence) [<a href="#rid106">106</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Conversion to open surgery – 1.8 percent [<a href="#rid107">107</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Readmission – Open radical prostatectomy 5.5 percent, RARP 3.5 percent [<a href="#rid108">108</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Reoperation – Both open and robotic radical prostatectomy 1 percent [<a href="#rid108">108</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Venous thromboembolic events – 1.4 percent [<a href="#rid109">109</a>], lymphadenectomy increased incidence by four- to eightfold [<a href="#rid105">105</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocele – 0 to 8 percent [<a href="#rid110">110</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Urine (anastomotic) leak – Open radical prostatectomy 1 percent, RARP 2 percent [<a href="#rid111">111-114</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Bladder neck contracture/urethral stricture – Open radical prostatectomy 8 to 11 percent, RARP 1 to 2 percent (see <a class="local">'Urethral strictures'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>Rare (&lt;1 percent) – Obturator nerve injury, rectal injury or fistula, vascular injury, lower extremity compartment syndrome</p><p></p><p>A retrospective analysis of 13,924 radical prostatectomies at a single institution reported that 10.8, 7.9, 3.4, 2.6, and 0.9 percent of patients suffered a Clavien-Dindo class I, II, IIIa, IIIb, and IV/V complication, respectively  (<a class="graphic graphic_table graphicRef110852" href="/z/d/graphic/110852.html" rel="external">table 1</a>). The most common minor (class I or II) complications were lymphoceles or lymph leak (6.0 percent), blood transfusions (3.6 percent), urological infections (3.4 percent), or acute urinary retention after removal of the catheter (2.0 percent) [<a href="#rid115">115</a>]. The most common serious (class III or above) complications were infected lymphocele, hematoma or abscess requiring percutaneous drainage (3.3 percent), or persistent lymphocele requiring laparoscopic marsupialization (1.3 percent). Life-threatening complications were rare (0.9 percent). Compared with open radical prostatectomy, RARP was associated with less blood loss, shorter catheter time, and lower risk of Clavien-Dindo Grade II and III complications.</p><p>In a 2022 prospective multicenter comparison of open and robotic radical prostatectomy by the PROST-QA/RP2 consortium, RARP was associated with less mean intraoperative blood loss (192 versus 805 mL); a shorter mean hospital stay (1.6 versus 2.1 days); and fewer blood transfusions (1 versus 4 percent), wound infections (2 versus 4 percent), other infections (1 versus 4 percent), deep venous thromboses (0.5 versus 2 percent), and bladder neck contractures requiring dilation (1.6 versus 8.3 percent) compared with open radical prostatectomy [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H24079785"><span class="h2">Oncologic outcomes</span><span class="headingEndMark"> — </span>Histopathologic examination of the resection specimen permits pathologic staging, which may differ significantly from the pretreatment clinical stage  (<a class="graphic graphic_table graphicRef110728" href="/z/d/graphic/110728.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef110729" href="/z/d/graphic/110729.html" rel="external">table 3</a>). The more accurate assessment of the extent of disease provides a better correlation with prognosis in determining whether further therapy is indicated. (See  <a class="medical medical_review" href="/z/d/html/6934.html" rel="external">"Prostate cancer: Postoperative management of pathologic stage T3 disease, positive surgical margins, and lymph node involvement following radical prostatectomy", section on 'Pathologic versus clinical staging'</a>.)</p><p>The relationship between pathologic staging and prognosis is illustrated by a multicenter series of 23,910 men who were managed with radical prostatectomy at four centers between 1987 and 2005 [<a href="#rid116">116</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prostate-cancer-specific mortality at 15 years was a function of the pathologic stage of disease (0.8 to 1.5 percent, 2.9 to 10.0 percent, 15 to 27 percent, and 22 to 30 percent for pT2, pT3a, pT3b, and pN1 disease, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 15 year prostate-cancer-specific mortality rates also correlated with higher Gleason score (0.2 to 1.2 percent, 4.2 to 6.5 percent, 6.6 to 11 percent, and 26 to 37 percent at 15 years for Gleason scores ≤6 or less, 3+4, 4+3, and 8 to 10, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The identification of higher pathologic stage (pT3 or pT4), microscopic lymph node involvement (pN1), or Gleason score 8 to 10 in the resection specimen did not preclude prolonged survival in a majority of cases. Depending upon age, the approximate overall survival rates at 15 years for men with Gleason score 8 to 10 disease were 50 to 60 percent; for those with seminal vesicle invasion, 50 to 70 percent; and for those with microscopic lymph node involvement, 60 to 65 percent.</p><p></p><p>However, these results cannot be generalized to men who present with clinical T3 or T4 disease or clinical evidence of lymph node involvement.</p><p>In a study of 428 patients followed for a median of 15.5 years (interquartile range 14.6 to 16.6 years) after radical prostatectomy, adverse pathology (positive margins, seminal vesicle invasion, extracapsular extension, or detectable prostate-specific antigen [PSA]) was highly associated with distant metastasis (hazard ratio [HR] 12.30, 95% CI 5.30-28.55) and prostate-cancer-specific mortality (HR 10.03, 95% CI 3.42-29.47) [<a href="#rid117">117</a>].</p><p>Multiple molecular prognostic tests are emerging, with the goal of improving risk stratification beyond that of pathologic staging. In a study of 428 patients followed for up to 20 years after radical prostatectomy, the Oncotype DX Genomic Prostate Score (GPS) result was highly associated with oncologic outcomes. Per 20 unit increase in GPS, multivariable analysis estimated hazard ratios of 2.24 (95% CI 1.49-3.53) and 2.30 (95% CI 1.45-4.36) for distant metastasis and prostate-cancer-specific mortality, respectively [<a href="#rid118">118</a>]. (See  <a class="medical medical_review" href="/z/d/html/94751.html" rel="external">"Molecular prognostic tests for prostate cancer"</a>.)</p><p>Importantly, the occurrence of an isolated PSA recurrence following radical prostatectomy is not necessarily associated with the rapid development of more extensive disease. (See  <a class="medical medical_review" href="/z/d/html/6950.html" rel="external">"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification", section on 'Risk of metastases or death'</a>.)</p><p class="headingAnchor" id="H355856201"><span class="h1">SPECIAL CONSIDERATIONS DURING THE COVID-19 PANDEMIC</span><span class="headingEndMark"> — </span>The COVID-19 pandemic has increased the complexity of cancer care. Important issues include balancing the risk from delaying cancer treatment versus harm from COVID-19, minimizing the number of clinic and hospital visits to reduce exposure whenever possible, mitigating the negative impacts of social distancing on delivery of care, and appropriately and fairly allocating limited healthcare resources. Specific guidance for decision-making for cancer surgery on a disease-by-disease basis is available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.facs.org%2Ffor-medical-professionals%2Fcovid-19%2Fclinical-guidance%2Felective-case%2F&amp;token=xKVKR5TkZQ%2BcnQEF%2BgJlY9hiGhCq31DqqIwoe6dFs%2B3gZuJGC8rPf1pP%2FdDTj5Ri3akAT9e5fsTsYityWYqbZWpU1IocIoEFv8DK3XS%2BAAKvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=6944" target="_blank">American College of Surgeons</a>, from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.surgonc.org%2Fresources%2Fcovid-19-resources%2F&amp;token=5aVSqxTAW76%2FfxOFXm77eUulkHUzWKYFVR%2B5EN4jxO3Op8sFH%2BZN22dtBGjugKXhOyo3zGi9ZFVHuAUXBICiUA%3D%3D&amp;TOPIC_ID=6944" target="_blank">Society for Surgical Oncology</a>, and from others. These and other recommendations for cancer care during active phases of the COVID-19 pandemic are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer"</a>.) </p><p class="headingAnchor" id="H1246842288"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117831.html" rel="external">"Society guideline links: Diagnosis and management of prostate cancer"</a>.)</p><p class="headingAnchor" id="H24077890"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/85795.html" rel="external">"Patient education: Choosing treatment for low-risk localized prostate cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics</p><p></p><p class="headingAnchor" id="H24077897"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – In patients with clinically localized prostate cancer, the preferred approaches for definitive therapy include radical prostatectomy and radiation therapy (RT); the choice is largely a matter of patient preference. Radical prostatectomy is generally not indicated for patients with distant metastases or when there is tumor fixation to adjacent structures. (See <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical treatment</strong> – Radical prostatectomy is the standard approach for most patients who choose surgery for the definitive management of their prostate cancer. We recommend robotic-assisted radical prostatectomy over an open procedure due to improved perioperative outcomes (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Indeed, in resource-rich countries, such as the United States, radical prostatectomy is most commonly performed robotically. (See <a class="local">'Surgical treatment'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nerve-sparing approach</strong> – For patients with no evidence of tumor involving the neurovascular bundle, we recommend that a nerve-sparing approach be incorporated into the radical prostatectomy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). This approach is associated with faster return of urinary continence and a lower frequency of impotence in men who were potent prior to surgery. (See <a class="local">'Nerve-sparing approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Perineal prostatectomy</strong> – Perineal prostatectomy is an alternative to retropubic prostatectomy for men with clinical stage T1-2 disease, a relatively small prostate gland, and no indication for a lymph node dissection. This approach may be particularly useful in men who have had prior abdominal surgery. Perineal prostatectomy should be limited to centers with expertise in this technique. (See <a class="local">'Perineal radical prostatectomy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pelvic lymph node dissection</strong> – For patients choosing radical prostatectomy as their primary definitive therapy, we suggest performing an extended pelvic lymph node dissection when the risk of lymph node metastasis is estimated to be greater than 2 to 5 percent (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This risk is estimated using one of the nomograms selected by individual surgeons/centers. Extended dissection may be especially beneficial to those with very-high-risk disease. (See  <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">"Localized prostate cancer: Risk stratification and choice of initial treatment"</a> and <a class="local">'Pelvic lymph node dissection'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up treatment</strong> – After radical prostatectomy, patients with adverse laboratory or pathology features (eg, positive margins, seminal vesicle invasion, extracapsular extension, or detectable prostate-specific antigen [PSA]) should consider postoperative adjuvant or early salvage radiation therapy. (See <a class="local">'Follow-up after surgery'</a> above and <a class="local">'Oncologic outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functional outcomes</strong> – The most important frequent complications associated with radical prostatectomy include urinary incontinence and erectile dysfunction. (See <a class="local">'Functional outcomes'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges Eric A Klein, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl 1995; 172:65.</a></li><li><a class="nounderline abstract_t">Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367:203.</a></li><li><a class="nounderline abstract_t">Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014; 370:932.</a></li><li><a class="nounderline abstract_t">Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med 2017; 377:132.</a></li><li><a class="nounderline abstract_t">Wilt TJ, Ullman KE, Linskens EJ, et al. Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review. J Urol 2021; 205:967.</a></li><li><a class="nounderline abstract_t">Bill-Axelson A, Holmberg L, Garmo H, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med 2018; 379:2319.</a></li><li><a class="nounderline abstract_t">Wilt TJ, Vo TN, Langsetmo L, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol 2020; 77:713.</a></li><li><a class="nounderline abstract_t">Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 2016; 375:1415.</a></li><li><a class="nounderline abstract_t">Donovan JL, Hamdy FC, Lane JA, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2016; 375:1425.</a></li><li><a class="nounderline abstract_t">O'Shaughnessy MJ, McBride SM, Vargas HA, et al. A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology 2017; 102:164.</a></li><li><a class="nounderline abstract_t">Parker PA, Pettaway CA, Babaian RJ, et al. The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2009; 27:3169.</a></li><li><a class="nounderline abstract_t">Bekelman JE, Rumble RB, Chen RC, et al. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol 2018; 36:3251.</a></li><li><a class="nounderline abstract_t">Trinh QD, Sammon J, Sun M, et al. Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol 2012; 61:679.</a></li><li><a class="nounderline abstract_t">Sooriakumaran P, Srivastava A, Shariat SF, et al. A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients. Eur Urol 2014; 66:450.</a></li><li><a class="nounderline abstract_t">Howard JM. Robotic, Laparoscopic, and Open Radical Prostatectomy-Is the Jury Still Out? JAMA Netw Open 2021; 4:e2120693.</a></li><li><a class="nounderline abstract_t">Chang P, Wagner AA, Regan MM, et al. Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. J Urol 2022; 207:127.</a></li><li><a class="nounderline abstract_t">Lantz A, Bock D, Akre O, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021; 80:650.</a></li><li><a class="nounderline abstract_t">Wu SY, Chang CL, Chen CI, Huang CC. Comparison of Acute and Chronic Surgical Complications Following Robot-Assisted, Laparoscopic, and Traditional Open Radical Prostatectomy Among Men in Taiwan. JAMA Netw Open 2021; 4:e2120156.</a></li><li><a class="nounderline abstract_t">Ilic D, Evans SM, Allan CA, et al. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. Cochrane Database Syst Rev 2017; 9:CD009625.</a></li><li><a class="nounderline abstract_t">Yaxley JW, Coughlin GD, Chambers SK, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 2016.</a></li><li><a class="nounderline abstract_t">Coughlin GD, Yaxley JW, Chambers SK, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncol 2018; 19:1051.</a></li><li><a class="nounderline abstract_t">Stolzenburg JU, Holze S, Neuhaus P, et al. Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01). Eur Urol 2021; 79:750.</a></li><li><a class="nounderline abstract_t">Trinh QD, Bjartell A, Freedland SJ, et al. A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol 2013; 64:786.</a></li><li><a class="nounderline abstract_t">Vickers A, Bianco F, Cronin A, et al. The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point. J Urol 2010; 183:1360.</a></li><li><a class="nounderline abstract_t">Vickers AJ, Savage CJ, Hruza M, et al. The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. Lancet Oncol 2009; 10:475.</a></li><li><a class="nounderline abstract_t">Secin FP, Savage C, Abbou C, et al. The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol 2010; 184:2291.</a></li><li><a class="nounderline abstract_t">Thompson JE, Egger S, Böhm M, et al. Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases. Eur Urol 2014; 65:521.</a></li><li><a class="nounderline abstract_t">Sivaraman A, Sanchez-Salas R, Prapotnich D, et al. Learning curve of minimally invasive radical prostatectomy: Comprehensive evaluation and cumulative summation analysis of oncological outcomes. Urol Oncol 2017; 35:149.e1.</a></li><li><a class="nounderline abstract_t">Gershman B, Psutka SP, McGovern FJ, et al. Patient-reported Functional Outcomes Following Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy Performed by High-volume Surgeons at High-volume Hospitals. Eur Urol Focus 2016; 2:172.</a></li><li><a class="nounderline abstract_t">Wilson CA, Aminsharifi A, Sawczyn G, et al. Outpatient Extraperitoneal Single-Port Robotic Radical Prostatectomy. Urology 2020; 144:142.</a></li><li><a class="nounderline abstract_t">Abaza R, Martinez O, Ferroni MC, et al. Same Day Discharge after Robotic Radical Prostatectomy. J Urol 2019; 202:959.</a></li><li><a class="nounderline abstract_t">Abaza R, Murphy C, Bsatee A, et al. Single-port Robotic Surgery Allows Same-day Discharge in Majority of Cases. Urology 2021; 148:159.</a></li><li><a class="nounderline abstract_t">Nguyen LN, Head L, Witiuk K, et al. The Risks and Benefits of Cavernous Neurovascular Bundle Sparing during Radical Prostatectomy: A Systematic Review and Meta-Analysis. J Urol 2017; 198:760.</a></li><li><a class="nounderline abstract_t">Galfano A, Di Trapani D, Sozzi F, et al. Beyond the learning curve of the Retzius-sparing approach for robot-assisted laparoscopic radical prostatectomy: oncologic and functional results of the first 200 patients with ≥ 1 year of follow-up. Eur Urol 2013; 64:974.</a></li><li><a class="nounderline abstract_t">Freire MP, Weinberg AC, Lei Y, et al. Anatomic bladder neck preservation during robotic-assisted laparoscopic radical prostatectomy: description of technique and outcomes. Eur Urol 2009; 56:972.</a></li><li><a class="nounderline abstract_t">Rosenberg JE, Jung JH, Edgerton Z, et al. Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer. Cochrane Database Syst Rev 2020; 8:CD013641.</a></li><li><a class="nounderline abstract_t">Martis G, Diana M, Ombres M, et al. Retropubic versus perineal radical prostatectomy in early prostate cancer: eight-year experience. J Surg Oncol 2007; 95:513.</a></li><li><a class="nounderline abstract_t">Ramirez D, Maurice MJ, Kaouk JH. Robotic perineal radical prostatectomy and pelvic lymph node dissection using a purpose-built single-port robotic platform. BJU Int 2016; 118:829.</a></li><li><a class="nounderline abstract_t">Kaouk JH, Akca O, Zargar H, et al. Descriptive Technique and Initial Results for Robotic Radical Perineal Prostatectomy. Urology 2016; 94:129.</a></li><li><a class="nounderline abstract_t">Lenfant L, Garisto J, Sawczyn G, et al. Robot-assisted Radical Prostatectomy Using Single-port Perineal Approach: Technique and Single-surgeon Matched-paired Comparative Outcomes. Eur Urol 2021; 79:384.</a></li><li><a class="nounderline abstract_t">Ni K, Xue D, Li G. Transperineal single-port robot-assisted radical prostatectomy with Si da Vinci surgical system: initial experience and description of technique. Transl Cancer Res 2021; 10:4694.</a></li><li><a class="nounderline abstract_t">Carbonara U, Minafra P, Papapicco G, et al. Xi Nerve-sparing Robotic Radical Perineal Prostatectomy: European Single-center Technique and Outcomes. Eur Urol Open Sci 2022; 41:55.</a></li><li><a class="nounderline abstract_t">Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy: oncological outcome during a 20-year period. J Urol 1999; 161:163.</a></li><li><a class="nounderline abstract_t">Lance RS, Freidrichs PA, Kane C, et al. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. BJU Int 2001; 87:61.</a></li><li><a class="nounderline abstract_t">Berglund RK, Sadetsky N, DuChane J, et al. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. J Urol 2007; 177:526.</a></li><li><a class="nounderline abstract_t">Allaf ME, Palapattu GS, Trock BJ, et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004; 172:1840.</a></li><li><a class="nounderline abstract_t">Abdollah F, Suardi N, Gallina A, et al. Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. Ann Oncol 2013; 24:1459.</a></li><li><a class="nounderline abstract_t">Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis 2016; 19:395.</a></li><li><a class="nounderline abstract_t">Negoita S, Feuer EJ, Mariotto A, et al. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer 2018; 124:2801.</a></li><li><a class="nounderline abstract_t">Jemal A, Culp MB, Ma J, et al. Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening. J Natl Cancer Inst 2021; 113:64.</a></li><li><a class="nounderline abstract_t">Siegel DA, O'Neil ME, Richards TB, et al. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep 2020; 69:1473.</a></li><li><a class="nounderline abstract_t">Montironi R, Cimadamore A, Gasparrini S, et al. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. Expert Rev Anticancer Ther 2018; 18:685.</a></li><li><a class="nounderline abstract_t">Böttcher R, Kweldam CF, Livingstone J, et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer 2018; 18:8.</a></li><li><a class="nounderline abstract_t">Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol 2022; 208:19.</a></li><li><a class="nounderline abstract_t">Fossati N, Willemse PM, Van den Broeck T, et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol 2017; 72:84.</a></li><li><a class="nounderline abstract_t">Briganti A, Larcher A, Abdollah F, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012; 61:480.</a></li><li><a class="nounderline abstract_t">Gandaglia G, Soligo M, Battaglia A, et al. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. Eur Urol 2019; 75:817.</a></li><li><a class="nounderline abstract_t">Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170:1798.</a></li><li><a class="nounderline abstract_t">Gandaglia G, Ploussard G, Valerio M, et al. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. Eur Urol 2019; 75:506.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Prostate cancer. Version 1.2023 — September 16, 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (Accessed on October 03, 2022).</li><li class="breakAll">European Association of Urology (EAU). Guidelines - Prostate cancer. Available at: https://uroweb.org/guidelines/prostate-cancer (Accessed on October 03, 2022).</li><li><a class="nounderline abstract_t">Lestingi JFP, Guglielmetti GB, Trinh QD, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol 2021; 79:595.</a></li><li><a class="nounderline abstract_t">Touijer KA, Sjoberg DD, Benfante N, et al. Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. Eur Urol Oncol 2021; 4:532.</a></li><li><a class="nounderline abstract_t">Gondoputro W, Scheltema MJ, Blazevski A, et al. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer. J Nucl Med 2022; 63:1659.</a></li><li><a class="nounderline abstract_t">Hermsen R, Wedick EBC, Vinken MJM, et al. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference. Eur J Nucl Med Mol Imaging 2022; 49:3929.</a></li><li><a class="nounderline abstract_t">Klein EA, Kattan M, Stephenson A, Vickers A. How many lymphadenectomies does it take to cure one patient? Eur Urol 2008; 53:13.</a></li><li><a class="nounderline abstract_t">Zwergel U, Lehmann J, Wullich B, et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J Urol 2004; 171:1128.</a></li><li><a class="nounderline abstract_t">Wawroschek F, Wagner T, Hamm M, et al. The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 2003; 43:132.</a></li><li><a class="nounderline abstract_t">Mattei A, Fuechsel FG, Bhatta Dhar N, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008; 53:118.</a></li><li><a class="nounderline abstract_t">Ramotar M, Chua MLK, Truong H, et al. Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. Urol Oncol 2022; 40:5.e1.</a></li><li><a class="nounderline abstract_t">Alshalalfa M, Crisan A, Vergara IA, et al. Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 2015; 116:556.</a></li><li><a class="nounderline abstract_t">Agochukwu-Mmonu N, Murali A, Wittmann D, et al. Development and Validation of Dynamic Multivariate Prediction Models of Sexual Function Recovery in Patients with Prostate Cancer Undergoing Radical Prostatectomy: Results from the MUSIC Statewide Collaborative. Eur Urol Open Sci 2022; 40:1.</a></li><li><a class="nounderline abstract_t">Kundu SD, Roehl KA, Eggener SE, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004; 172:2227.</a></li><li><a class="nounderline abstract_t">Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000; 55:58.</a></li><li><a class="nounderline abstract_t">Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358:1250.</a></li><li><a class="nounderline abstract_t">Sivarajan G, Prabhu V, Taksler GB, et al. Ten-year outcomes of sexual function after radical prostatectomy: results of a prospective longitudinal study. Eur Urol 2014; 65:58.</a></li><li><a class="nounderline abstract_t">Lee JK, Assel M, Thong AE, et al. Unexpected Long-term Improvements in Urinary and Erectile Function in a Large Cohort of Men with Self-reported Outcomes Following Radical Prostatectomy. Eur Urol 2015; 68:899.</a></li><li><a class="nounderline abstract_t">Raina R, Agarwal A, Zippe CD. Management of erectile dysfunction after radical prostatectomy. Urology 2005; 66:923.</a></li><li><a class="nounderline abstract_t">Lowentritt BH, Scardino PT, Miles BJ, et al. Sildenafil citrate after radical retropubic prostatectomy. J Urol 1999; 162:1614.</a></li><li><a class="nounderline abstract_t">Kwon YS, Farber N, Yu JW, et al. Longitudinal recovery patterns of penile length and the underexplored benefit of long-term phosphodiesterase-5 inhibitor use after radical prostatectomy. BMC Urol 2018; 18:37.</a></li><li><a class="nounderline abstract_t">Hong EK, Lepor H, McCullough AR. Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Int J Impot Res 1999; 11 Suppl 1:S15.</a></li><li><a class="nounderline abstract_t">Hansen ST, Lund M, Ostergaard LD, Lund L. Role of regenerative therapies on erectile dysfunction after radical prostatectomy. Int J Impot Res 2021; 33:488.</a></li><li><a class="nounderline abstract_t">Rho BY, Kim SH, Ryu JK, et al. Efficacy of Low-Intensity Extracorporeal Shock Wave Treatment in Erectile Dysfunction Following Radical Prostatectomy: A Systematic Review and Meta-Analysis. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Mulhall JP, Parker M, Waters BW, Flanigan R. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int 2010; 105:37.</a></li><li><a class="nounderline abstract_t">Raina R, Pahlajani G, Agarwal A, et al. Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU Int 2010; 106:1719.</a></li><li><a class="nounderline abstract_t">Mulhall JP, Bella AJ, Briganti A, et al. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med 2010; 7:1687.</a></li><li><a class="nounderline abstract_t">Garcia FJ, Brock G. Current state of penile rehabilitation after radical prostatectomy. Curr Opin Urol 2010; 20:234.</a></li><li><a class="nounderline abstract_t">McCullough AR, Hellstrom WG, Wang R, et al. Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol 2010; 183:2451.</a></li><li><a class="nounderline abstract_t">Montorsi F, Brock G, Lee J, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54:924.</a></li><li><a class="nounderline abstract_t">Montorsi F, Brock G, Stolzenburg JU, et al. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). Eur Urol 2014; 65:587.</a></li><li><a class="nounderline abstract_t">Noh TI, Shim JS, Kang SG, et al. Efficacy of Tadalafil in Penile Rehabilitation Started Before Nerve-Sparing Robot-Assisted Radical Prostatectomy: A Double-Blind Pilot Study. Sex Med 2022; 10:100508.</a></li><li><a class="nounderline abstract_t">Jang SW, Lee EH, Chun SY, et al. Comparison of the efficacy of the early LI-SWT plus daily tadalafil with daily tadalafil only as penile rehabilitation for postprostatectomy erectile dysfunction. Int J Impot Res 2023; 35:447.</a></li><li><a class="nounderline abstract_t">Sood A, Grauer R, Jeong W, et al. Evaluating post radical prostatectomy mechanisms of early continence. Prostate 2022; 82:1186.</a></li><li><a class="nounderline abstract_t">Hoeh B, Hohenhorst JL, Wenzel M, et al. Full functional-length urethral sphincter- and neurovascular bundle preservation improves long-term continence rates after robotic-assisted radical prostatectomy. J Robot Surg 2023; 17:177.</a></li><li><a class="nounderline abstract_t">Pinkhasov RM, Lee T, Huang R, et al. Prediction of Incontinence after Robot-Assisted Radical Prostatectomy: Development and Validation of a 24-Month Incontinence Nomogram. Cancers (Basel) 2022; 14.</a></li><li><a class="nounderline abstract_t">Prabhu V, Sivarajan G, Taksler GB, et al. Long-term continence outcomes in men undergoing radical prostatectomy for clinically localized prostate cancer. Eur Urol 2014; 65:52.</a></li><li><a class="nounderline abstract_t">Zhang AY, Bodner DR, Fu AZ, et al. Effects of Patient Centered Interventions on Persistent Urinary Incontinence after Prostate Cancer Treatment: A Randomized, Controlled Trial. J Urol 2015; 194:1675.</a></li><li><a class="nounderline abstract_t">Geraerts I, Van Poppel H, Devoogdt N, et al. Influence of preoperative and postoperative pelvic floor muscle training (PFMT) compared with postoperative PFMT on urinary incontinence after radical prostatectomy: a randomized controlled trial. Eur Urol 2013; 64:766.</a></li><li><a class="nounderline abstract_t">Montgomery JS, Gayed BA, Daignault S, et al. Early urinary retention after catheter removal following radical prostatectomy predicts for future symptomatic urethral stricture formation. Urology 2007; 70:324.</a></li><li><a class="nounderline abstract_t">Elliott SP, Meng MV, Elkin EP, et al. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol 2007; 178:529.</a></li><li><a class="nounderline abstract_t">Yurkanin JP, Dalkin BL, Cui H. Evaluation of cold knife urethrotomy for the treatment of anastomotic stricture after radical retropubic prostatectomy. J Urol 2001; 165:1545.</a></li><li><a class="nounderline abstract_t">Slova D, Lepor H. The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms. J Urol 2007; 178:2397.</a></li><li><a class="nounderline abstract_t">Xu AJ, Taksler GB, Llukani E, Lepor H. Long-term Natural History of Lower Urinary Tract Symptoms Following Radical Retropubic Prostatectomy: A Prospective 15-Year Longitudinal Study. Urology 2018; 120:167.</a></li><li><a class="nounderline abstract_t">Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005; 97:1525.</a></li><li><a class="nounderline abstract_t">Van Hemelrijck M, Garmo H, Holmberg L, et al. Thromboembolic events following surgery for prostate cancer. Eur Urol 2013; 63:354.</a></li><li><a class="nounderline abstract_t">Redondo C, Rozet F, Velilla G, et al. [Complications of radical prostatectomy.]. Arch Esp Urol 2017; 70:766.</a></li><li><a class="nounderline abstract_t">Sharma V, Meeks JJ. Open conversion during minimally invasive radical prostatectomy: impact on perioperative complications and predictors from national data. J Urol 2014; 192:1657.</a></li><li><a class="nounderline abstract_t">Pilecki MA, McGuire BB, Jain U, et al. National multi-institutional comparison of 30-day postoperative complication and readmission rates between open retropubic radical prostatectomy and robot-assisted laparoscopic prostatectomy using NSQIP. J Endourol 2014; 28:430.</a></li><li><a class="nounderline abstract_t">Tollefson MK, Karnes RJ, Rangel L, et al. Blood type, lymphadenectomy and blood transfusion predict venous thromboembolic events following radical prostatectomy with pelvic lymphadenectomy. J Urol 2014; 191:646.</a></li><li><a class="nounderline abstract_t">Khoder WY, Trottmann M, Seitz M, et al. Management of pelvic lymphoceles after radical prostatectomy: a multicentre community based study. Eur J Med Res 2011; 16:280.</a></li><li><a class="nounderline abstract_t">Tewari A, Sooriakumaran P, Bloch DA, et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol 2012; 62:1.</a></li><li><a class="nounderline abstract_t">Chang CM, Moon D, Gianduzzo TR, Eden CG. The impact of prostate size in laparoscopic radical prostatectomy. Eur Urol 2005; 48:285.</a></li><li><a class="nounderline abstract_t">Robertson C, Close A, Fraser C, et al. Relative effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of localised prostate cancer: a systematic review and mixed treatment comparison meta-analysis. BJU Int 2013; 112:798.</a></li><li><a class="nounderline abstract_t">Gotto GT, Yunis LH, Vora K, et al. Impact of prior prostate radiation on complications after radical prostatectomy. J Urol 2010; 184:136.</a></li><li><a class="nounderline abstract_t">Pompe RS, Beyer B, Haese A, et al. Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems. BJU Int 2018; 122:801.</a></li><li><a class="nounderline abstract_t">Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185:869.</a></li><li><a class="nounderline abstract_t">Brooks MA, Thomas L, Magi-Galluzzi C, et al. Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. Urol Oncol 2022; 40:104.e1.</a></li><li><a class="nounderline abstract_t">Brooks MA, Thomas L, Magi-Galluzzi C, et al. GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality. JCO Precis Oncol 2021; 5.</a></li></ol></div><div id="topicVersionRevision">Topic 6944 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8578259" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22808955" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Radical prostatectomy versus observation for localized prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24597866" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Radical prostatectomy or watchful waiting in early prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28700844" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33350857" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30575473" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32089359" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27626136" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27626365" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27888148" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349551" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30183466" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22206800" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24290695" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34432015" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Robotic, Laparoscopic, and Open Radical Prostatectomy-Is the Jury Still Out?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34433304" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34538508" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34432012" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of Acute and Chronic Surgical Complications Following Robot-Assisted, Laparoscopic, and Traditional Open Radical Prostatectomy Among Men in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28895658" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30017351" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33573861" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23664423" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A systematic review of the volume-outcome relationship for radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171687" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19342300" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20952022" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The learning curve for laparoscopic radical prostatectomy: an international multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24287319" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28117215" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Learning curve of minimally invasive radical prostatectomy: Comprehensive evaluation and cumulative summation analysis of oncological outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28723533" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Patient-reported Functional Outcomes Following Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy Performed by High-volume Surgeons at High-volume Hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32619598" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Outpatient Extraperitoneal Single-Port Robotic Radical Prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31112102" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Same Day Discharge after Robotic Radical Prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33217457" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Single-port Robotic Surgery Allows Same-day Discharge in Majority of Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28286069" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The Risks and Benefits of Cavernous Neurovascular Bundle Sparing during Radical Prostatectomy: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23856036" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Beyond the learning curve of the Retzius-sparing approach for robot-assisted laparoscopic radical prostatectomy: oncologic and functional results of the first 200 patients with≥1 year of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19781848" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Anatomic bladder neck preservation during robotic-assisted laparoscopic radical prostatectomy: description of technique and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32813279" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17226809" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Retropubic versus perineal radical prostatectomy in early prostate cancer: eight-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27410172" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Robotic perineal radical prostatectomy and pelvic lymph node dissection using a purpose-built single-port robotic platform.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27233935" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Descriptive Technique and Initial Results for Robotic Radical Perineal Prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33357990" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Robot-assisted Radical Prostatectomy Using Single-port Perineal Approach: Technique and Single-surgeon Matched-paired Comparative Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35116324" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Transperineal single-port robot-assisted radical prostatectomy with Si da Vinci surgical system: initial experience and description of technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35633830" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Xi Nerve-sparing Robotic Radical Perineal Prostatectomy: European Single-center Technique and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10037390" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Radical perineal prostatectomy: oncological outcome during a 20-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11121994" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222625" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15540734" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23508825" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27431496" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Increasing incidence of metastatic prostate cancer in the United States (2004-2013).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29786851" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32432713" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33056955" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29699428" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29295717" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35536148" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28126351" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22078338" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30409676" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14532779" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30342844" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30342844" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30342844" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33293077" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33865797" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35241483" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35543733" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900798" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : How many lymphadenectomies does it take to cure one patient?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767285" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Lymph node positive prostate cancer: long-term survival data after radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12565770" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709171" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34538726" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25762434" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35638089" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Development and Validation of Dynamic Multivariate Prediction Models of Sexual Function Recovery in Patients with Prostate Cancer Undergoing Radical Prostatectomy: Results from the MUSIC Statewide Collaborative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15538237" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10654895" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Patient-reported urinary continence and sexual function after anatomic radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18354103" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Quality of life and satisfaction with outcome among prostate-cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24007711" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Ten-year outcomes of sexual function after radical prostatectomy: results of a prospective longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26293181" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Unexpected Long-term Improvements in Urinary and Erectile Function in a Large Cohort of Men with Self-reported Outcomes Following Radical Prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286096" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Management of erectile dysfunction after radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10524880" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Sildenafil citrate after radical retropubic prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29739455" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Longitudinal recovery patterns of penile length and the underexplored benefit of long-term phosphodiesterase-5 inhibitor use after radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10554925" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33452520" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Role of regenerative therapies on erectile dysfunction after radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35628901" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Efficacy of Low-Intensity Extracorporeal Shock Wave Treatment in Erectile Dysfunction Following Radical Prostatectomy: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19659465" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20394611" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Long-term potency after early use of a vacuum erection device following radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20388165" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Erectile function rehabilitation in the radical prostatectomy patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20224415" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Current state of penile rehabilitation after radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20403617" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18640769" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24169081" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35395569" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Efficacy of Tadalafil in Penile Rehabilitation Started Before Nerve-Sparing Robot-Assisted Radical Prostatectomy: A Double-Blind Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35347300" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Comparison of the efficacy of the early LI-SWT plus daily tadalafil with daily tadalafil only as penile rehabilitation for postprostatectomy erectile dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35579026" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Evaluating post radical prostatectomy mechanisms of early continence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35459985" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Full functional-length urethral sphincter- and neurovascular bundle preservation improves long-term continence rates after robotic-assisted radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35406416" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Prediction of Incontinence after Robot-Assisted Radical Prostatectomy: Development and Validation of a 24-Month Incontinence Nomogram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23957946" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Long-term continence outcomes in men undergoing radical prostatectomy for clinically localized prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26231554" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effects of Patient Centered Interventions on Persistent Urinary Incontinence after Prostate Cancer Treatment: A Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23357349" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Influence of preoperative and postoperative pelvic floor muscle training (PFMT) compared with postoperative PFMT on urinary incontinence after radical prostatectomy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17826498" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Early urinary retention after catheter removal following radical prostatectomy predicts for future symptomatic urethral stricture formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17570425" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11342914" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Evaluation of cold knife urethrotomy for the treatment of anastomotic stricture after radical retropubic prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17936841" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29953883" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Long-term Natural History of Lower Urinary Tract Symptoms Following Radical Retropubic Prostatectomy: A Prospective 15-Year Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234566" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021972" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Thromboembolic events following surgery for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29099379" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : [Complications of radical prostatectomy.]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24936721" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Open conversion during minimally invasive radical prostatectomy: impact on perioperative complications and predictors from national data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24251547" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : National multi-institutional comparison of 30-day postoperative complication and readmission rates between open retropubic radical prostatectomy and robot-assisted laparoscopic prostatectomy using NSQIP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140843" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Blood type, lymphadenectomy and blood transfusion predict venous thromboembolic events following radical prostatectomy with pelvic lymphadenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810563" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Management of pelvic lymphoceles after radical prostatectomy: a multicentre community based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22405509" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963634" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The impact of prostate size in laparoscopic radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23890416" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Relative effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of localised prostate cancer: a systematic review and mixed treatment comparison meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20478594" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Impact of prior prostate radiation on complications after radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29727912" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239008" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Predicting 15-year prostate cancer specific mortality after radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34824014" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34036236" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
